1. Introduction

Post-marketing surveillance (PMS) is a critical phase in the lifecycle of any pharmaceutical product or medical device. It involves the systematic monitoring and evaluation of a product’s safety and effectiveness after it has been released into the market. This white paper delves into the transformative potential of risk-based approaches to PMS, offering insights into how these strategies can optimize resource allocation and enhance patient safety.1–3

1.1 The Evolving Landscape of Post-Marketing Surveillance

The landscape of PMS is continually evolving, driven by factors such as:2,3

These changes require a shift from traditional, reactive PMS models to proactive, risk-based strategies.

1.2 Challenges in Resource Allocation

Traditional PMS methods often involve blanket approaches that allocate resources uniformly across all products, regardless of their risk profiles. This can lead to inefficiencies and missed opportunities to address critical safety concerns. Key challenges in resource allocation include:3,4

1.3 Purpose and Scope of This White Paper

This white paper aims to provide a comprehensive overview of risk-based approaches to PMS and their potential to optimize resource allocation. It will explore the key principles of risk-based monitoring, discuss methodologies for risk assessment, and provide practical guidance on implementing a risk-based surveillance plan. The paper will also examine the role of technology in enabling more efficient and effective PMS, and highlight case studies and best practices from industry leaders. This paper also covers the regulatory considerations and compliance requirements. And the metrics for measuring success and driving continuous improvement. The scope of this paper encompasses pharmaceutical products and medical devices, with a focus on global regulatory requirements and expectations.

2. Understanding Post-Marketing Surveillance

Post-marketing surveillance (PMS) is the practice of monitoring the safety of a pharmaceutical drug or medical device after it has been released on the market. It is an important part of the science of pharmacovigilance. Also known as Phase IV clinical trials, PMS is designed to detect any rare or long-term adverse effects over a much larger subject population and longer period of time than was possible during the Phase I-III clinical trials.4,5

2.1 Regulatory Requirements and Expectations

Regulatory bodies worldwide, including the FDA in the United States and the EMA in Europe, mandate post-marketing surveillance to ensure the ongoing safety and efficacy of approved products. Key requirements and expectations include:5–8

• Adverse Event Reporting: Manufacturers must report serious adverse events (SAEs) to regulatory agencies within specified timeframes.
• Periodic Safety Update Reports (PSURs): These reports provide a comprehensive overview of a product’s safety profile, including cumulative safety data and risk-benefit assessments.
• Risk Management Plans (RMPs): RMPs outline strategies for identifying, minimizing, and managing risks associated with a product.
• Post-Approval Studies: Regulatory agencies may require manufacturers to conduct post-approval studies to further evaluate a product’s safety or efficacy.

Failure to comply with these requirements can result in regulatory action, including product recalls, fines, and loss of market authorization.

2.2 Types of Post-Marketing Studies

Various types of studies are employed in post-marketing surveillance to gather data and assess safety signals:3,8

• Observational Studies: These studies observe patients in real-world settings without intervention. Examples include cohort studies, case-control studies, and cross-sectional studies.
• Registries: Registries collect data on patients with specific conditions or who have received specific treatments.
• Spontaneous Reporting Systems: These systems collect reports of adverse events submitted by healthcare professionals, patients, and manufacturers.
• Active Surveillance Systems: These systems proactively collect data on adverse events from healthcare providers and patients.
• Meta-Analyses: Synthesize data from multiple studies to provide a more comprehensive assessment of a product’s safety profile.

2.3 Current Industry Practices

Many pharmaceutical and medical device companies still rely on traditional, reactive approaches to PMS. These approaches typically involve manual review of adverse event reports and other safety data, operate within siloed systems that lack integration across data sources, and make limited use of advanced technologies such as analytics and automation. In many cases, the primary emphasis is placed on regulatory compliance rather than on proactive risk identification and management. As a result, these practices are often inefficient and may hinder the timely detection, assessment, and mitigation of potential safety concerns.3,5,9

3. The Risk-Based Framework

A risk-based framework for post-marketing surveillance is a structured approach that prioritizes monitoring activities and resource allocation based on the level of risk associated with a product. This framework enables organizations to focus their efforts on the areas where they can have the greatest impact on patient safety and public health.3

3.1 Principles of Risk-Based Monitoring

The core principles of risk-based monitoring include:3,10,11

3.2 Risk Assessment Methodologies

Several methodologies can be used to assess the risk associated with a product, including:3,11,12

1. Failure Mode and Effects Analysis (FMEA): A systematic approach to identifying potential failure modes and their effects.
2. Hazard Analysis and Critical Control Points (HACCP): A preventive approach to identifying and controlling hazards.
3. Quantitative Risk Assessment (QRA): A mathematical approach to quantifying risk based on the probability and severity of potential adverse events.
4. Delphi Method: A structured communication technique used to gather expert opinions and build consensus.

3.3 Risk Categorization and Prioritization

Once risks have been assessed, they should be categorized and prioritized based on their potential impact. A common approach is to use a risk matrix that plots the probability of an event against its severity.12–14

Risk Matrix Example

• High-Risk: These risks have a high probability of occurrence and a significant impact on patient safety.
• Medium-Risk: These risks have a moderate probability of occurrence and a moderate impact on patient safety.
• Low-Risk: These risks have a low probability of occurrence and a minimal impact on patient safety.

• By categorizing risks, organizations can prioritize their monitoring efforts and allocate resources accordingly
• Products and signals categorized as high risk should be given the highest priority for monitoring and mitigation.

4. Key Risk Factors in Post-Marketing Surveillance

Identifying and understanding key risk factors is crucial for effective risk-based post-marketing surveillance. These factors can be broadly categorized into product-related risks, patient population considerations, market and geographic factors, and data quality and signal detection challenges.14–17

4.1 Product-Related Risks

Product-related risks encompass inherent characteristics and potential issues associated with the pharmaceutical or medical device itself. These include:12,14

1. Novelty and Complexity: New molecular entities or devices with complex mechanisms of action may have less established safety profiles.
2. Known Safety Signals: Products with pre-existing safety concerns identified during clinical trials require heightened vigilance.
3. Manufacturing Issues: Production problems, such as contamination or deviations from approved processes, can introduce new risks.
4. Drug-Drug Interactions: The potential for interactions with other medications can increase the risk of adverse events.
5. Device Malfunctions: Mechanical or software failures in medical devices can lead to patient harm.

4.2 Patient Population Considerations

The characteristics of the patient population exposed to a product can significantly influence its risk profile. Factors to consider include:16

1. Age and Comorbidities: Elderly patients and those with multiple underlying health conditions may be more vulnerable to adverse events.
2. Genetic Predisposition: Genetic factors can influence a patient’s response to a drug or device.
3. Pregnancy and Lactation: Special considerations apply to products used during pregnancy or lactation.
4. Pediatric Use: Children may respond differently to medications and devices than adults.
5. Specific Subgroups: Certain demographic or ethnic groups may be at higher risk of adverse events.

4.3 Market and Geographic Factors

Market and geographic factors can also impact the risk associated with a product. These include:17

1. Market Size and Penetration: Products with widespread use may have a higher likelihood of detecting rare adverse events.
2. Geographic Variations: Differences in healthcare practices, environmental factors, and genetic backgrounds can influence a product’s safety profile in different regions.
3. Counterfeit Products: The presence of counterfeit or substandard products can pose a significant risk to patient safety.
4. Off-Label Use: Using a product for indications not approved by regulatory agencies can increase the risk of adverse events.

4.4 Data Quality and Signal Detection

High-quality data and effective signal detection mechanisms are essential for identifying and managing risks. Challenges in this area include:15

1. Data Completeness and Accuracy: Incomplete or inaccurate data can mask safety signals.
2. Data Silos: A lack of integration between different data sources can hinder signal detection.
3. Reporting Bias: Underreporting or selective reporting of adverse events can distort the true risk profile.
4. Signal-to-Noise Ratio: Distinguishing true safety signals from background noise can be challenging.
5. Timeliness of Reporting: Delays in reporting adverse events can impede timely risk mitigation efforts.

5. Optimizing Resource Allocation

Optimizing resource allocation in post-marketing surveillance is crucial for maximizing the effectiveness of monitoring activities while minimizing costs. A strategic approach involves careful resource assessment and planning, leveraging technology and automation, adopting appropriate organizational structures, and effectively managing vendors and partners.18–20

5.1 Resource Assessment and Planning

Effective resource allocation in post-marketing surveillance begins with a comprehensive assessment of available resources and a clear definition of monitoring objectives. This process involves evaluating the budget allocated to PMS activities to identify constraints and potential cost-saving opportunities, as well as assessing staffing needs to ensure the appropriate number of personnel with the required expertise are in place. It also includes reviewing the existing technology infrastructure to determine its adequacy and identify areas where enhancements or automation may improve efficiency. In parallel, organizations must identify and evaluate available data sources—such as spontaneous adverse event reports, clinical trial data, and real-world evidence—to ensure comprehensive safety monitoring. Finally, applying a risk-based prioritization approach allows resources to be strategically allocated toward products with higher risk profiles, thereby maximizing the impact of PMS efforts and improving patient safety.19

5.2 Technology and Automation Solutions

Technology and automation play a critical role in enhancing the efficiency and effectiveness of post-marketing surveillance activities. Advanced adverse event management systems help streamline the collection, processing, and regulatory reporting of safety data, reducing manual effort and errors. Data mining and signal detection tools enable the automated analysis of large and diverse datasets to identify potential safety signals at an early stage. Robotic process automation (RPA) further improves efficiency by automating repetitive and time-consuming tasks, such as data entry, case processing, and report generation. In addition, natural language processing (NLP) technologies facilitate the extraction and interpretation of relevant safety information from unstructured data sources, including medical records, literature, and social media, thereby supporting more comprehensive and timely safety monitoring.20

5.3 Centralized vs. Decentralized Approaches

The optimal organizational structure for PMS depends on the size and complexity of the organization. Options include:19

1. Centralized Approach: A single, dedicated team responsible for all PMS activities.
2. Decentralized Approach: PMS activities distributed across different departments or business units.
3. Hybrid Approach: A combination of centralized and decentralized elements, with a central team providing oversight and guidance to decentralized units.

5.4 Vendor and Partner Management

Many organizations rely on vendors and partners to support their PMS activities. Effective vendor management is essential for ensuring data quality, compliance, and cost-effectiveness. Key considerations include:18,19

1. Due Diligence: Thoroughly vetting potential vendors and partners to ensure they have the necessary expertise and resources.
2. Contract Negotiation: Negotiating clear and comprehensive contracts that outline roles, responsibilities, and performance metrics.
3. Performance Monitoring: Regularly monitoring vendor performance to ensure they are meeting expectations.
4. Data Security and Privacy: Implementing appropriate measures to protect sensitive data.

6. Implementation Strategies

Successfully implementing a risk-based approach to post-marketing surveillance requires a well-defined plan, strong stakeholder engagement, comprehensive training, and robust quality management systems.21–23

6.1 Developing a Risk-Based Surveillance Plan

A risk-based surveillance plan outlines the strategies and procedures for monitoring the safety of products after they have been released to market. Key elements of the plan include:21

1. Risk Assessment Methodology: Defining the approach for identifying and assessing risks associated with each product.
2. Data Sources: Identifying the data sources that will be used to monitor safety, including spontaneous reports, clinical trials, and real-world data.
3. Signal Detection Procedures: Describing the processes for identifying and evaluating potential safety signals.
4. Risk Mitigation Strategies: Outlining the actions that will be taken to mitigate identified risks.
5. Communication Plan: Defining how safety information will be communicated to stakeholders, including regulatory agencies, healthcare professionals, and patients.
6. Performance Metrics: Establishing key performance indicators (KPIs) for measuring the effectiveness of the surveillance plan.

6.2 Stakeholder Engagement

Engaging stakeholders is a critical success factor for the effective implementation of a risk-based post-marketing surveillance program. Collaboration with regulatory agencies ensures alignment with regulatory expectations, supports compliance, and enables timely guidance on safety-related issues. Active engagement with healthcare professionals is essential to encourage accurate and timely reporting of adverse events and to obtain valuable clinical insights into real-world product use. Incorporating patient perspectives and feedback further enhances PMS activities by providing firsthand information on safety experiences and outcomes. In addition, close collaboration among internal departments—such as clinical development, regulatory affairs, quality, and marketing—supports a coordinated and integrated approach to safety management, enabling more effective risk identification, communication, and mitigation across the product lifecycle.21

6.3 Training and Change Management

Implementing a risk-based approach requires training and change management to ensure that all stakeholders understand the new processes and procedures. Key activities include:22

1. Training Programs: Developing and delivering training programs on risk assessment, signal detection, and risk mitigation.
2. Communication Campaigns: Communicating the benefits of the risk-based approach and addressing any concerns or resistance to change.
3. Change Management Strategies: Implementing strategies to support the transition to the new approach, such as providing mentorship and coaching.

6.4 Quality Management Systems

A robust quality management system is essential for ensuring the accuracy, reliability, and consistency of PMS activities. Key elements of the QMS include:23

1. Standard Operating Procedures (SOPs): Developing and implementing SOPs for all PMS activities.
2. Data Quality Controls: Implementing controls to ensure the accuracy and completeness of data.
3. Audits and Inspections: Conducting regular audits and inspections to identify and address any deficiencies in the QMS.
4. Corrective and Preventive Actions (CAPA): Implementing CAPA plans to address identified issues and prevent recurrence.

7. Technology Enablers

Technology plays a pivotal role in enabling risk-based post-marketing surveillance, offering tools and capabilities to manage and analyze vast amounts of data, identify potential safety signals, and streamline operations. Real-world data, artificial intelligence, data analytics, and electronic health records integration are key technology enablers.24–26

7.1 Real-World Data and Evidence

Real-world data (RWD) and real-world evidence (RWE) are increasingly valuable in post-marketing surveillance. RWD includes data collected outside of traditional clinical trials, such as electronic health records, claims data, and patient registries. RWE is the evidence derived from the analysis of RWD.24–26

The benefits of RWD and RWE in PMS include:

1. Larger Sample Sizes: RWD enables the analysis of data from much larger patient populations than traditional clinical trials.
2. Real-World Settings: RWD reflects how products are used in real-world clinical practice.
3. Longitudinal Data: RWD provides longitudinal data on patient outcomes over time.
4. Identification of Rare Events: RWD can help identify rare adverse events that may not be detected in clinical trials.

7.2 Artificial Intelligence and Machine Learning

Artificial intelligence (AI) and machine learning (ML) are transforming post-marketing surveillance by automating tasks, improving signal detection, and personalizing risk management. AI and ML applications in PMS include:25

1. Automated Signal Detection: AI and ML algorithms can automatically scan large datasets for potential safety signals.
2. Predictive Analytics: AI and ML can predict which patients are at highest risk of adverse events.
3. Personalized Risk Management: AI and ML can tailor risk management strategies to individual patients.
4. Natural Language Processing (NLP): NLP can extract information from unstructured text, such as medical records and social media posts.

7.3 Data Analytics and Visualization Tools

Data analytics and visualization tools are essential for making sense of the vast amounts of data generated in post-marketing surveillance. These tools enable analysts to identify patterns, trends, and anomalies that may indicate safety concerns. Key features of data analytics and visualization tools include:24

1. Interactive Dashboards: Providing real-time insights into key performance indicators.
2. Data Mining Algorithms: Identifying hidden patterns and relationships in data.
3. Statistical Analysis: Performing statistical analysis to assess the significance of safety signals.
4. Geospatial Analysis: Mapping adverse events to identify geographic clusters.

7.4 Electronic Health Records Integration

Integrating electronic health records (EHRs) with PMS systems can provide a wealth of real-world data on patient outcomes and adverse events. EHR integration can enable:26

1. Automated Data Extraction: Automatically extracting relevant data from EHRs for PMS analysis.
2. Real-Time Monitoring: Monitoring patient safety in real-time.
3. Improved Data Quality: Enhancing the accuracy and completeness of data.
4. Patient-Centric Monitoring: Incorporating patient-reported outcomes into PMS.

8. Case Studies and Best Practices

Examining case studies and best practices provides valuable insights into how organizations have successfully implemented risk-based approaches to post-marketing surveillance. These examples highlight the benefits of a risk-based approach and offer practical guidance for implementation.26,27

8.1 Successful Implementation Examples

Several organizations have successfully implemented risk-based PMS programs. Examples include:

• A pharmaceutical company implemented a risk-based monitoring system that prioritized products based on their risk profiles, resulting in a 30% reduction in adverse event reporting costs.
• A medical device manufacturer used real-world data to identify a previously unknown safety signal associated with one of its products, leading to a product recall and improved patient safety.
• A regulatory agency implemented a risk-based inspection program that focused on manufacturers with a history of compliance issues, resulting in improved compliance rates.

8.2 Lessons Learned

Implementing a Risk based approach 27,28

8.3 Industry Benchmarking

Benchmarking against industry peers can provide valuable insights into best practices for risk-based PMS. Key areas for benchmarking include:23,29

1. Risk Assessment Methodologies: Comparing different risk assessment methodologies and selecting the most appropriate approach.
2. Data Sources: Evaluating the data sources used by other organizations and identifying opportunities for improvement.
3. Technology Solutions: Assessing the technology solutions used by other organizations and identifying potential investments.
4. Performance Metrics: Comparing performance metrics and setting realistic goals.
5. Organizational Structure: Evaluating different organizational structures and selecting the most effective model.

9. Regulatory Considerations

Navigating the regulatory landscape is crucial for implementing a successful risk-based post-marketing surveillance program. Understanding FDA guidance, EMA requirements, global harmonization efforts, and compliance and audit readiness is essential.29–32

9.1 FDA Guidance and Expectations

The U.S. Food and Drug Administration (FDA) provide guidance on post-marketing surveillance requirements for pharmaceutical products and medical devices. Key guidance documents include:30,32

1. Postmarketing Studies and Clinical Trials – Implementation of Section 505(o) of the Federal Food, Drug, and Cosmetic Act: Provides guidance on post-approval study requirements.
2. Guidance for Industry: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment: Outlines best practices for pharmacovigilance and pharmacoepidemiologic assessment.
3. Medical Device Reporting (MDR): Describes the requirements for reporting adverse events associated with medical devices.

9.2 EMA Requirements

The European Medicines Agency (EMA) sets the standards for post-marketing surveillance in Europe. Key requirements include:31

1. Risk Management Plans (RMPs): Requiring manufacturers to develop and implement RMPs to identify, minimize, and manage risks associated with their products.
2. Periodic Safety Update Reports (PSURs): Requiring manufacturers to submit PSURs to regulatory authorities on a regular basis.
3. Signal Management: Establishing processes for detecting, validating, and assessing safety signals.

9.3 Global Harmonization Efforts

Global harmonization efforts aim to standardize regulatory requirements for post-marketing surveillance across different countries. Key initiatives include:31

1. International Council for Harmonisation (ICH): Developing guidelines for pharmaceutical development and regulation.
2. World Health Organization (WHO): Promoting the development of pharmacovigilance systems in developing countries.
3. Council for International Organizations of Medical Sciences (CIOMS): Developing guidelines for ethical conduct in medical research.

9.4 Compliance and Audit Readiness

Maintaining compliance with regulatory requirements and being prepared for audits is essential for a successful PMS program. Key steps include:31,32

1. Developing and Implementing SOPs: Creating standard operating procedures for all PMS activities.
2. Training Personnel: Ensuring that all personnel are properly trained on regulatory requirements.
3. Conducting Internal Audits: Regularly conducting internal audits to identify and address any deficiencies in the PMS program.
4. Maintaining Documentation: Maintaining complete and accurate documentation of all PMS activities.

10. Measuring Success

Measuring the success of a risk-based post-marketing surveillance program is crucial for demonstrating its value, identifying areas for improvement, and ensuring that it is meeting its objectives. Key performance indicators (KPIs), return on investment (ROI) analysis, and continuous improvement initiatives are essential components of a successful measurement strategy.33,34

10.1 Key Performance Indicators

Key performance indicators (KPIs) provide a quantitative measure of the effectiveness of a risk-based PMS program. Examples of relevant KPIs include:33,34

1. Number of safety signals detected: Measures the effectiveness of signal detection activities.
2. Time to signal detection: Measures the speed at which safety signals are identified.
3. Number of risk mitigation actions taken: Measures the responsiveness to identified risks.
4. Reduction in adverse event rates: Measures the impact of risk mitigation actions on patient safety.
5. Compliance with regulatory requirements: Measures the adherence to regulatory standards.
6. Cost savings: Measures the efficiency of resource allocation.

10.2 Return on Investment

Calculating the return on investment (ROI) of a risk-based PMS program can help demonstrate its value to stakeholders. ROI can be calculated by dividing the benefits of the program by its costs. Examples of benefits include:33,34

1. Reduced adverse event costs: Cost savings associated with preventing adverse events.
2. Reduced regulatory fines: Cost savings associated with avoiding regulatory penalties.
3. Improved brand reputation: Increased revenue associated with a positive brand image.
4. Increased patient safety: Societal benefits associated with improved patient outcomes.

10.3 Continuous Improvement

Continuous improvement is an ongoing process of identifying and implementing changes to improve the effectiveness and efficiency of a risk-based PMS program. Key steps in the continuous improvement process include:34

1. Data Analysis: Analyzing data to identify areas for improvement.
2. Root Cause Analysis: Identifying the underlying causes of problems.
3. Developing and Implementing Solutions: Developing and implementing solutions to address identified problems.
4. Monitoring Performance: Monitoring performance to ensure that the solutions are effective.
5. Feedback Loops: Establishing feedback loops to gather input from stakeholders.

11. Future Trends and Innovations

The field of post-marketing surveillance is continually evolving, driven by emerging technologies, predictive analytics, and patient-centric approaches. These trends and innovations hold the potential to transform PMS and improve patient safety.3,25,35–37

11.1 Emerging Technologies

Several emerging technologies are poised to revolutionize post-marketing surveillance. These include:3,23,36

1. Blockchain: Enhancing data security and transparency.
2. Wearable Sensors: Collecting real-time data on patient health and behavior.
3. Artificial Intelligence: Creating new opportunities for data analysis and signal detection.
4. Cloud Computing: Providing scalable and cost-effective data storage and processing.

11.2 Predictive Analytics

Predictive analytics uses statistical models and machine learning algorithms to predict future outcomes based on historical data. Predictive analytics can be used in PMS to:3,23,37

1. Identify patients at high risk of adverse events: Predictive models can identify patients who are likely to experience adverse events based on their medical history, demographics, and lifestyle factors.
2. Predict the likelihood of product recalls: Predictive models can identify products that are likely to be recalled based on manufacturing data, adverse event reports, and customer feedback.
3. Forecast the impact of risk mitigation strategies: Predictive models can forecast the impact of different risk mitigation strategies on patient safety and healthcare costs.

11.3 Patient-Centric Approaches

Patient-centric approaches to PMS involve actively engaging patients in the monitoring process. Key elements of patient-centric PMS include:3,35

1. Patient-Reported Outcomes (PROs): Collecting data directly from patients on their experiences with a product.
2. Patient Advisory Boards: Establishing patient advisory boards to provide input on PMS activities.
3. Social Media Monitoring: Monitoring social media for patient feedback and adverse event reports.
4. Mobile Apps: Developing mobile apps to enable patients to report adverse events and access safety information.

By embracing these future trends and innovations, organizations can enhance the effectiveness and efficiency of their post-marketing surveillance programs and improve patient safety.

12. Conclusion and Recommendations

Risk-based approaches to post-marketing surveillance offer a significant opportunity to optimize resource allocation, enhance patient safety, and improve the overall effectiveness of PMS programs. By prioritizing monitoring activities based on the level of risk associated with a product, organizations can focus their efforts on the areas where they can have the greatest impact.

Key Recommendations:

• Implement a risk-based framework: Develop a structured approach for identifying, assessing, and prioritizing risks associated with products.
• Leverage technology and automation: Invest in technology to automate tasks, improve data analysis, and streamline operations.
• Engage stakeholders: Involve stakeholders from across the organization and externally to ensure buy-in and support.
• Embrace continuous improvement: Continuously monitor performance and make adjustments as needed.
• Stay informed about emerging trends and innovations: Keep abreast of the latest technologies, predictive analytics, and patient-centric approaches.

By following these recommendations, organizations can create a robust and effective risk-based PMS program that protects patients, enhances product safety, and contributes to public health.

References:

1. Ding Y, Markatou M, Ball R. An evaluation of statistical approaches to postmarketing surveillance. Stat Med. 2020;39(7):845-874. doi:10.1002/sim.8447
2. Badnjević A, Pokvić LG, Deumić A, Bećirović LS. Post-market surveillance of medical devices: A review. Technol Health Care Off J Eur Soc Eng Med. 2022;30(6):1315-1329. doi:10.3233/THC-220284
3. Alomar M, Tawfiq AM, Hassan N, Palaian S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther Adv Drug Saf. 2020;11:2042098620938595. doi:10.1177/2042098620938595
4. Zhang X, Zhang Y, Ye X, Guo X, Zhang T, He J. Overview of phase IV clinical trials for postmarket drug safety surveillance: a status report from the ClinicalTrials.gov registry. BMJ Open. 2016;6(11):e010643. doi:10.1136/bmjopen-2015-010643
5. Trailokya A, Srivastava A, Mukaddam Q, et al. Phase IV Studies: What Clinicians Need to Know! J Assoc Physicians India. 2024;72(1):85-87. doi:10.59556/japi.71.0444
6. Haque A, Daniel S, Maxwell T, Boerstoel M. Postmarketing Surveillance Studies-An Industry Perspective on Changing Global Requirements and Implications. Clin Ther. 2017;39(4):675-685. doi:10.1016/j.clinthera.2017.03.011
7. D’souza J, Nandave M, Blöchlinger R. Discrepancies in regulations in post-marketing safety surveillance of drug-device combination products in the EU and US: a review. Front Drug Saf Regul. 2025;5:1609455. doi:10.3389/fdsfr.2025.1609455
8. Sharrar RG, Dieck GS. Monitoring product safety in the postmarketing environment. Ther Adv Drug Saf. 2013;4(5):211-219. doi:10.1177/2042098613490780
9. Weaver J, Willy M, Avigan M. Informatic tools and approaches in postmarketing pharmacovigilance used by FDA. AAPS J. 2008;10(1):35-41. doi:10.1208/s12248-007-9004-5
10. Vlahović-Palčevski V, Mentzer D. Postmarketing surveillance. Handb Exp Pharmacol. 2011;205:339-351. doi:10.1007/978-3-642-20195-0_17
11. O’Neill RT. Biostatistical considerations in pharmacovigilance and pharmacoepidemiology: linking quantitative risk assessment in pre-market licensure application safety data, post-market alert reports and formal epidemiological studies. Stat Med. 1998;17(15-16):1851-1858; discussion 1859-1862. doi:10.1002/(sici)1097-0258(19980815/30)17:15/16%3C1851::aid-sim987%3E3.0.co;2-z
12. Rigaud M, Buekers J, Bessems J, et al. The methodology of quantitative risk assessment studies. Environ Health Glob Access Sci Source. 2024;23(1):13. doi:10.1186/s12940-023-01039-x
13. Arnetz JE, Hamblin L, Ager J, et al. Application and implementation of the hazard risk matrix to identify hospital workplaces at risk for violence. Am J Ind Med. 2014;57(11):1276-1284. doi:10.1002/ajim.22371
14. Kaya GK, Ward J, Clarkson J. A Review of Risk Matrices Used in Acute Hospitals in England. Risk Anal Off Publ Soc Risk Anal. 2019;39(5):1060-1070. doi:10.1111/risa.13221
15. Lucas S, Ailani J, Smith TR, Abdrabboh A, Xue F, Navetta MS. Pharmacovigilance: reporting requirements throughout a product’s lifecycle. Ther Adv Drug Saf. 2022;13:20420986221125006. doi:10.1177/20420986221125006
16. Sandberg L, Taavola H, Aoki Y, Chandler R, Norén GN. Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase. Drug Saf. 2020;43(10):999-1009. doi:10.1007/s40264-020-00957-w
17. Raj N, Fernandes S, Charyulu NR, Dubey A, G S R, Hebbar S. Postmarket surveillance: a review on key aspects and measures on the effective functioning in the context of the United Kingdom and Canada. Ther Adv Drug Saf. 2019;10:2042098619865413. doi:10.1177/2042098619865413
18. Menang O, Kuemmerle A, Maigetter K, Burri C. Strategies and interventions to strengthen pharmacovigilance systems in low-income and middle-income countries: a scoping review. BMJ Open. 2023;13(9):e071079. doi:10.1136/bmjopen-2022-071079
19. Lewis DJ, McCallum JF. Utilizing Advanced Technologies to Augment Pharmacovigilance Systems: Challenges and Opportunities. Ther Innov Regul Sci. 2020;54(4):888-899. doi:10.1007/s43441-019-00023-3
20. Schmider J, Kumar K, LaForest C, Swankoski B, Naim K, Caubel PM. Innovation in Pharmacovigilance: Use of Artificial Intelligence in Adverse Event Case Processing. Clin Pharmacol Ther. 2019;105(4):954-961. doi:10.1002/cpt.1255
21. Bahri P, Pariente A. Systematising Pharmacovigilance Engagement of Patients, Healthcare Professionals and Regulators: A Practical Decision Guide Derived from the International Risk Governance Framework for Engagement Events and Discourse. Drug Saf. 2021;44(11):1193-1208. doi:10.1007/s40264-021-01111-w
22. Endale Biru S, Wallelign TM, Gedif Fenta T. Implementation Status and Challenges of Pharmacovigilance Program in Ethiopia: A Mixed-Methods Study. Inq J Health Care Organ Provis Financ. 2024;61:00469580241287752. doi:10.1177/00469580241287752
23. Bassi P, Kaur N, Rana S, Kaur A, Malik DS. Insight Review on Data Quality Management in Pharmacovigilance. Curr Drug Saf. Published online April 14, 2025. doi:10.2174/0115748863344567250327085214
24. Ledieu T, Bouzillé G, Polard E, Plaisant C, Thiessard F, Cuggia M. Clinical Data Analytics With Time-Related Graphical User Interfaces: Application to Pharmacovigilance. Front Pharmacol. 2018;9:717. doi:10.3389/fphar.2018.00717
25. Algarvio RC, Conceição J, Rodrigues PP, Ribeiro I, Ferreira-da-Silva R. Artificial intelligence in pharmacovigilance: a narrative review and practical experience with an expert-defined Bayesian network tool. Int J Clin Pharm. 2025;47(4):932-944. doi:10.1007/s11096-025-01975-3
26. Dimitsaki S, Natsiavas P, Jaulent MC. Applying AI to Structured Real-World Data for Pharmacovigilance Purposes: Scoping Review. J Med Internet Res. 2024;26:e57824. doi:10.2196/57824
27. Gavin KM, Sundermann ML, Wieland A. Leveraging real-world data for safety signal detection and risk management in pre- and post-market settings. Front Drug Saf Regul. 2025;5:1626822. doi:10.3389/fdsfr.2025.1626822
28. Lu Z. Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives. Drug Healthc Patient Saf. 2009;1:35-45. doi:10.2147/dhps.s7180
29. Guzman J, O’Connell E, Kikule K, Hafner T. The WHO Global Benchmarking Tool: a game changer for strengthening national regulatory capacity. BMJ Glob Health. 2020;5(8):e003181. doi:10.1136/bmjgh-2020-003181
30. Potter E, Reyes M, Naples J, Dal Pan G. FDA Adverse Event Reporting System (FAERS) Essentials: A Guide to Understanding, Applying, and Interpreting Adverse Event Data Reported to FAERS. Clin Pharmacol Ther. 2025;118(3):567-582. doi:10.1002/cpt.3701
31. GVP. European Medicines Agency. Signal management overview. Describes PRAC’s role in prioritizing and evaluating safety signals post-authorization.
32. US FDA. Postmarket Drug Safety Information for Patients and Providers.
33. KPI. Pharmacovigilance Analytics. Pharmacovigilance Analytics.
34. KPI SOP. SOP for Pharmacovigilance Metrics and Key Performance Indicators (KPIs). SOP for Pharmacovigilance Metrics and Key Performance Indicators (KPIs).
35. Basch E. Patient-reported outcomes in drug safety evaluation. Ann Oncol. 2009;20(12):1905-1906. doi:10.1093/annonc/mdp542
36. Bate A, Hobbiger SF. Artificial Intelligence, Real-World Automation and the Safety of Medicines. Drug Saf. 2021;44(2):125-132. doi:10.1007/s40264-020-01001-7
37. Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93(6):539-546. doi:10.1038/clpt.2013.24